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Abstracts / International Journal of Surgery 8 (2010) 501–578 559Results: 85 patients (88 lesions) underwent laparoscopic resection during
this period. 84 lesions were visualised endoscopically. Of these, 52 (61.9%)
were tattooed. 36 (69%) were tattooed at ﬁrst endoscopy, 15 (28.8%) at
a further procedure, and one unknown. The tattoo was adjudged as visible
and accurate in 74%, visible but inaccurate in 9% and not visible in 17%.
There was no relationship between tattoo visibility and BMI (p ¼ 0.35) or
male sex (p ¼ 0.54). Of the 32 lesions visualised but not tattooed, 14 were
in the right colon and 6 in the rectum below the peritoneal reﬂection. No
tattoo-related complications were encountered.
Conclusion: The practice of tattooing colorectal lesions varies in
frequency and accuracy. We advocate that all suspicious lesions, except
perhaps mid-low rectal lesions, are tattooed at a deﬁned distance below
the tumour in case surgery is required.DETECTION OF CERVICAL LYMPH NODES IN HEAD AND NECK CANCER:
A STUDY OF THE CORRELATION BETWEEN ULTRASONIC AND
HISTOLOGICAL FINDINGS IN WALES
R. Khosla, D. Owens, J. Rees, A. Tomkinson. University Hospital Wales
Cardiff
The prognosis of patients with Head and Neck cancer relates to a degree on
the presence and region of local metastatic disease to the neck. Pre-
operatively it is essential that an accurate evaluation is undertaken so
effective treatment can be undertaken. Ultrasonography has been shown
to be effective in examining the cervical nodes and had become an
investigation of choice in Head and Neck surgery. A retrospective study of
50 patients with Head and Neck carcinoma was undertaken examining
each region of the neck for evidence of local metastatic disease. All patients
had undergone elective neck dissection which followed pre-operative
assessment with ultrasound. 29 (58% CI 48.21 and 67.2) were found to have
malignant lymphadenopathy on ultrasound examination compared with
27 (54% CI 44.26 and 63.44) on histological assessment. Correlation using
Kappa statistics for categorical data shows correlation at 0.96 or very good
agreement. Overall ultrasonography had high sensitivity and speciﬁcity
85% and 79% respectively. Positive and negative predictive values were
strong at 82% each although false positive and false negative rates of
detection were 21% and 15% respectively. Conclusion- Ultrasound remains
an effective pre-operative investigation in the assessment of Head and
Neck cancer with high correlation of results.BREAST CANCER SCREENING: WORTH THE PAIN?
P. Ravindra 1, D. Myers 2. 1 Royal Derby Hospital; 2 University of
Nottingham Medical School
Aims: In recent years, some parties have suggested that it is not worth
attending national breast cancer screening as it causes more harm than
beneﬁt. A recent study by Gotzsche et al (2009) concluded that the UK
national patient information leaﬂet should be revised to reﬂect this.
Methods: This study attempted to reproduce these results by retrospec-
tive analysis of all patients registered at one UK general practice invited to
be screened for breast cancer over a period of 21 years.
Results: A total of 1128 patients were invited to be screened over a 21-
year period. 97% had normal results. Out of 24 recalled, 6 resulted in
invasive investigations. It was extrapolated that for every 2000 women
screened for 10 years, two experienced false alarms and less than 1 (0.5)
underwent additional procedures. Patients were 100 times less likely to
experience a false alarm and 20 times less likely to undergo an invasive
procedure than suggested by Gotzsche et al.Conclusions: This audit demonstrated that the data presented by
detractors of the breast screening programme could not be reproduced in
a primary care population, thus presenting a strong argument as to why it
would be misleading to revise patient information leaﬂets.BLOOD TRANSFUSION IN GENERAL SURGERY; MSBOS GUIDELINES ARE
ACCURATE AND CAN DECREASE BLOOD WASTAGE
R.A.B. Thomas 1, H. Daniels 2, J. Duncan 2. 1Monklands Hospital,
Lanarkshire; 2Hairmyres Hospital, Lanarkshire
Background: Blood products are important for safe surgical practice but
limited. The local Maximum Surgical Blood Ordering Schedule (MSBOS)
simpliﬁes blood transfusion requests but is outdated. SIGN guidelines
recommend a cross-match:transfusion(CT) ratio of (1.5-2):1 ensuring
that over 50% of cross-matched units are transfused. In 2005, only 40%
were transfused. The remainder were potentially wasted. Aims To char-
acterise General Surgical blood use and assess MSBOS compliance over
eight weeks. To determine the CT ratio for elective General Surgical
patients.
Methods: All elective general surgical patients were included for eight
weeks. An individual patient proforma was completed with operative and
transfusion details. Cross-match requests and transfusions were conﬁrmed
by Blood Bank.
Results: In 104 elective admissions, there were 45 cross-match requests
with 126 units of blood cross-matched. 36 units were transfused and 90
units were returned. CT ratio was 3.5:1 (29%). 64% of operations followed
MSBOS. The remainder exceeded MSBOS.
Conclusion: Blood transfusion guidelines were not met. There was no
evidence that patient safety was compromised. If MSBOS had been fol-
lowed, the CT ratio would have been 2.2:1 (45%), closer to current guide-
lines.When blood requests exceededMSBOS recommendations, the excess
blood was never given.We have now simpliﬁed the schedule and educated
staff. Repeat audit is underway.HER2 POSITIVE BREAST CANCER AUDIT: IDENTIFICATION AND
AVAILABILITY OF RECEPTOR STATUS AND DECISION TO TREAT WITH
HERCEPTIN
J. Pottle, C. Bradshaw, N. Rudarakanchana, K. Hogben. Department of
Breast Surgery, Charing Cross Hospital, Imperial College Healthcare NHS
Trust
Introduction: HER2 receptor overexpression occurs in approximately 20%
of invasive breast cancers. These cancers tend to be more aggressive, with
a higher risk of recurrence. Although immunohistochemistry (IHC) can
determine HER2 status, results can be equivocal. Alternatively, the more
involved and expensive ﬂuorescent in situ hybridisation (FISH) can be
used. Using Herceptin, a monoclonal antibody against HER2 receptors, in
combination with chemotherapy can improve survival in late stage HER2
positive breast cancer.
Methods: Single unit retrospective study of 265 patients with invasive
breast cancer between 1st August 2008 and 31st July 2009.
Results: 15.5% of cancers were HER2 positive. Initially 15 patients had
equivocal results on IHC; 10 required FISH and 3 were subsequently found
to be HER2 positive. In 4%, HER2 status was not available at the multi-
disciplinary meeting. 27.5% of HER2 positive cancers did not receive
treatment with Herceptin, commonly because of co-morbidities or no
indication for chemotherapy.
